Conditions: Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 289
Healthy volunteers: no

Brief summary:
Comparison of fasting blood glucose levels in patients with Type 2 diabetes after 12 weeks of treatment with a new basal insulin analog or with insulin glargine.

Detailed description:
Patients in this study will continue to use their stable prestudy dose of metformin and/or a sulfonylurea. Prestudy therapy also includes once daily insulin glargine or neutral protamine Hagedorn (NPH) insulin. The 12-week active treatment phase will be followed by a 4-week follow-up period, during which patients will return to the basal insulin recommended by the investigator.

Arms:
arm 1: Participants took both LY2605541 and their pre-study insulin for first several days arm 2: Participants took only LY2605541 with first dose doubled arm 3: None

Interventions: intervention 1: LY2605541 intervention 2: insulin glargine
Intervention descriptions: intervention 1: subcutaneous injection of LY2605541 every morning with dose titration based on blood glucose measures for 12 weeks intervention 2: subcutaneous injection of insulin glargine every morning with dose titration based on blood glucose measures for 12 weeks

Protocol document: